Global hemophilia market is expected to reach USD 15.2 billion by 2024, according to a new report by Grand View Research, Inc. Increasing need for diagnosis of the target population in order to initiate prophylaxis treatment and supportive government programs is expected to be the vital impact rendering driver.
The market players are predicted to adopt strategies such as pipeline product development and geographic expansion in underdeveloped and developing regions, such as Middle Eastern and West African countries.
As of 2015, federal bodies such as the World Federation Hemophilia have vast information and treatment regulation in about 172 countries, of which 20 were added in 2013,including Nigeria, Togo, Mali, Zambia, Mauritania, and others.
Competitive pricing strategy is a vital factor promoting market players’ growth over the forecast period. For instance, Biogen launched Eloctate in 2014 in the U.S. at a lower price than the existing vastly used drug Advate.
View
summary of this report @ http://www.grandviewresearch.com/industry-analysis/hemophilia-treatment-industry
Further Key Findings From the Study Suggest:
·
Hemophilia B is expected to grow at a rapid rate
of over 6.0% during the forecast period. Higher emphasis on pipeline products
with an extended half-life and increasing incidence of hemophilia B affected
patients are expected to be the prominent growth factors.
·
On-demand treatment dominated the segment over
the forecast period and is expected to contribute more than 50.0% by 2024.
However, prophylaxis is expected to be the fastest growing segment because of
the requirement for better control of bleeding episodes and growing financial
assistance programs by healthcare providers and industry players.
·
For instance, Grifols has launched the
“AlphaNine SD Copay Card” and “ALPHANATE Copay Program” for immediate
enrollment in prophylaxis treatment by patients.
·
On the basis of therapy, gene therapy is
expected to be the fastest growing segment as a result of increasing R&D
and innovations in the field. Furthermore, replacement therapy is expected to
witness lucrative growth due to the launch of extended half-life versions of
currently available drugs.
·
For instance, Novo Nordisk is working on N8-GP,
CSL Behring is working on CSL689 rVIIa-FP, and Bayer is working on BAY
94-9027.These are expected to be commercially available around 2017/2018. This
is expected to improve treatment over the forecast period thereby boosting
growth.
·
Major market players include Biogen, Novo
Nordisk, Baxalta, Octapharma, CSL Behring, Pfizer, Inc., and Bayer Healthcare.
Most of the companies are actively involved in the awareness and treatment
programs launched by regional governments and hemophilia associations. Majority
of their products that are awaiting FDA approval have extended therapeutic use
in adults as well as children.
Browse
more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the global hemophilia market on the basis of type, treatment, therapy, and region.
Global Hemophilia Market by Type (USD Million), 2013 – 2024
·
Hemophilia A
·
Hemophilia B
·
Hemophilia C
·
Others
Global Hemophilia Market by Treatment (USD Million), 2013 – 2024
·
On-demand
·
Prophylaxis
Global Hemophilia Market Therapy(USD Million), 2013 – 2024
·
Replacement Therapy
·
Immune Tolerance Induction Therapy
·
Gene Therapy
Hemophilia Market By Region (USD Million), 2013 – 2024
·
North America
o
U.S.
o
Canada
·
Europe
o
UK
o
Germany
·
Asia-Pacific
o
Japan
o
China
·
Latin America
o
Brazil
o
Mexico
·
Middle East and Africa
o
South Africa
o
Saudi Arabia
For press release of this report - http://www.grandviewresearch.com/press-release/global-hemophilia-market
About Grand View
Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based
research across a range of industries including technology, chemicals,
materials, healthcare and energy.
Contact:
Sherry
James
Corporate
Sales Specialist, U.S.A.
Grand
View Research, Inc.
United
States
Phone: 1-415-349-0058
Toll
Free: 1-888-202-9519
Email: sales@grandviewresearch.com
No comments:
Post a Comment